Merck & Co. and Incyte unveiled closely watched data on a one-two punch with Keytruda and the experimental IDO1 inhibitor epacadostat.
Clovis may be the middle child among next-gen ovarian cancer meds, but it’s hoping new data will open the therapy to a wave of new patients.
Allergan is trying to fight off a cadre of generics makers intent on copying its blockbuster eye medication Restasis.
Shire has rolled out Mydayis, its new Adderall formulation, at a list price of $271 per month. The aim? Hitting $500 million in sales.
Merck KGaA has won European approval for its oral MS drug, but competing with more established rivals won't be easy.
Novartis’ Kisqali is playing from behind. But it just may have a shot at being No. 1 when it comes to snagging reimbursement in England.
What do constipation and gout have in common? Ironwood is leveraging its primary care sales force to hawk meds to treat both.
Pfizer’s Eucrisa debuted first in the next-gen eczema category, and its first national TV ad campaign marks a bid to press that first-mover advantage.
Seqirus has debuted its first commercial for Fluad, in an early flu season campaign targeting the 65-plus crowd.
GSK has formed an alliance with China’s e-commerce giant Alibaba to help promote HPV vaccine Cervarix.